Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics' stock has increased significantly, with a 283.31% increase over the past year. The company reported its Q4 and full-year 2025 operating results on March 26, 2026, with a net income of $31.5 million for Q4 2025 and $8.6 million for the full year. GSK resubmitted the New Drug Application for tebipenem HBr to the FDA in December 2025, with a PDUFA date set for June 18, 2026. The company's cash is expected to fund operations into 2028, partly due to a milestone payment from GSK. There have been reports of insider selling and an increase in short interest. Analyst sentiment is mixed.

The provided information does not indicate any specific demand seasonality for Spero Therapeutics' products or services. Demand is primarily driven by medical need rather than seasonal fluctuations.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Their pipeline includes Tebipenem HBr for complicated urinary tract infections, SPR720 for pulmonary non-tuberculous mycobacterial infections, and SPR206, a next-generation polymyxin. The company has licensing agreements with Meiji Seika Pharma Co., Ltd. for tebipenem pivoxil and tebipenem HBr, GSK for tebipenem HBr, and Everest Medicines for SPR206.

Spero Therapeutics is headquartered in Cambridge, Massachusetts, United States. The company has international reach through licensing agreements with GSK for tebipenem HBr in most territories, Meiji Seika Pharma Co., Ltd. in certain Asian territories, and Everest Medicines for SPR206 in Greater China, South Korea, and Southeast Asian countries.

Spero Therapeutics aims to deliver medicines for rare diseases and multi-drug resistant bacterial infections, embedding ESG considerations into its business strategies. Positive clinical trial results for tebipenem HBr, the FDA resubmission and PDUFA date, and the company's move to profitability have positively impacted its reputation.

Spero Therapeutics, Inc. is owned by 36.48% institutional shareholders, 62.44% Spero Therapeutics insiders, and 1.08% retail investors. Major institutional owners include Glaxosmithkline Plc, Pfizer Inc, and Vanguard Group Inc. Aquilo Capital Management LLC is the largest individual shareholder, owning 20.05% of the company.